Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA.

Dermatol Ther (Heidelb) · 2022 · PMC9021356 · PMID 35305255

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

Conclusion In this retrospective cohort study, patients initiating ustekinumab had a lower risk of treatment discontinuation and showed a numerical trend toward higher adherence relative to those initiating other biologics, including IL-17A antagonists.

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.